Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure

By sjmartinez • December 24, 2022

Talha KM, Fonarow GC, Virani SS, Butler J. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist Debakey Cardiovasc J. 2022 Dec 6;18(5):40-53. doi: 10.14797/mdcvj.1155. PMID: 36561085; PMCID: PMC9733124.

Tags: Cardiology/Epi, cardiovascular disease, glucagon-like peptide 1 receptor agonist, heart failure, prevention, Publications, sodium-glucose cotransporter-2 inhibitor

Treated HIV infection is not associated with carotid vascular inflammation or plaque progression as assessed by dynamic contrast magnetic resonance imaging

Shakil S, Chen D, Isquith D, Sapp J, Pommier I, Chu B, Guo Y, Canton G, Balu N, Yuan C, Hatsukami T, Maynard C, Zhao[...]

Differences in Ambulatory Care Outcomes Between Trainees and Faculty: A Multi-center Study

Graham KL, Amat M, Norian E, Li J, Weintraub J, Shaik A, Boggan JC, Davy J, Lyons A, Semour L, Rogers R, Davis RB. Differences[...]

Comparative assessment of CAC and SIS plaque burden categories via AI-guided quantitative CT analysis

Iskander B, Ichikawa K, Punnanithinont N, Kambalapalli S, Kinninger A, Krishnan S, Lakshmanan S, Roy S, Budoff MJ. Comparative assessment of CAC and SIS plaque[...]